BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.
https://link.springer.com/book/10.1007/978-3-031-94113-9
Related Questions
How will the announcement of precision diagnostics affect Bioxytran's valuation and stock price in the short term?
What is the expected timeline for commercializing the tissue oxygenation diagnostic platform and generating revenue?
Will the publication of the scientific work lead to new partnerships, licensing deals, or increased interest from pharmaceutical companies?
What regulatory pathways (e.g., FDA clearance) are required for the diagnostic product and how might they impact market entry timelines?
How significant is the potential market for stroke and Alzheimer’s diagnostics based on tissue oxygenation, and what share can Bioxytran realistically capture?
What are the projected costs and margins for the diagnostic platform once it reaches commercial scale?
Could the new precision diagnostics open up additional indications beyond stroke and Alzheimer’s, expanding the revenue opportunity?
How might this development influence analyst coverage, target price revisions, and overall investor sentiment toward Bioxytran?
How does Bioxytran's technology compare to existing competitors in the oxygen therapeutics and mitochondrial health space?
Are there any intellectual property protections or patents associated with the precision diagnostics that could provide a competitive moat?